Massive french study tracks Real-World use of diabetes drugs in over half a million patients
NCT ID NCT05882071
First seen Jan 11, 2026
Summary
This study analyzes health records from over 547,000 people in France who started taking SGLT2 inhibitors for type 2 diabetes between 2020 and 2024. Researchers will describe patient characteristics, prescription patterns, and track the occurrence of heart attacks, strokes, heart failure, kidney problems, and safety events like ketoacidosis. The goal is to understand how these drugs are used in everyday practice and their real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boehringer Ingelheim
Paris, 75013, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT2 inhibitors (a class of diabetes drugs)
What this could lead to
If successful, this study could help doctors understand how SGLT2 inhibitors are prescribed and their real-world effects on heart, kidney, and safety outcomes in people with type 2 diabetes.
What could go wrong
This is an observational study using existing health data, so it cannot prove cause and effect. Results may be influenced by factors not accounted for in the data.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.